Xeris Biopharma (XERS) Q3 2026 Earnings Call Transcript
Xeris Biopharma (XERS) reported Q3 2026 revenue growth of 44% YoY, driven by Recorlev, Gvoke, and KEVEYIS. Recorlev revenue increased 93% YoY to $71M. The company raised full-year revenue guidance to $395M-$405M and expects to reach $1B in revenue by 2030, up from a prior $750M outlook. Recorlev is now projected to hit $1B in annual net revenue 3-4 years sooner than previously expected. XERS also announced a new patent for KEVEYIS, extending its protection to 2043.
How this was made
The 30-second read
Why it matters
The guidance lift signals stronger demand for its rare‑disease products, likely prompting short‑term buying interest.
Market read
The new guidance could move XERS higher and influence sentiment in the rare‑disease biotech niche.
What to watch
Potential competition in Cushing syndrome treatments and the timing of XP‑8121 Phase III could temper long‑term growth.
Background
Xeris Biopharma (NASDAQ:XERS) reported its Q3 2026 earnings call, highlighting a 44% YoY revenue increase and raising its full‑year outlook.
Ticker impact
Xeris Biopharma raised full-year 2026 revenue guidance to $395M-$405M and outlined a path to $1B by 2030 after reporting Q3 2026 results.
upward pressure as investors price in higher future revenue.
Revenue growth of 44% YoY and a near‑term guidance increase are material new data for a small‑cap biotech.
Market effects
Biotech sector may see a modest rally as a peer demonstrates strong growth and raises guidance.
U.S. biotech investors could re‑allocate capital toward Xeris and similar rare‑disease firms.
Limited to niche rare‑disease market; no broad macro impact.
Counterpoint
If the guidance assumes continued payer reimbursement and no regulatory setbacks, the upside may be overstated.
Key entities
- companyXeris Biopharma
U.S. biotech focused on rare endocrine disorders.
